NetworkNewsAudio Archive - Page 3 of 22

MondayJun 10, 2019 6:30 pm

NetworkNewsAudio – INmune Bio Inc. (NASDAQ: INMB) Interview

About INmune Bio Inc. INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy,…

FridayJun 07, 2019 8:00 am

NetworkNewsAudio – Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) Meeting the Vital Communication Needs of First Responders

Related Editorial Communication platforms are ubiquitous, yet first responders still have difficulty communicating in emergencies. To meet the vital communication needs of first responders, Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) (SYATF Profile) leveraged its strong commercial experience in mission-critical communications systems and launched its FirstNet Ready Uniden® UV350, the first-to-market, in-vehicle device of its kind. FirstNet is being built in a public-private partnership with AT&T Inc. (NYSE: T) and the First Responder Network Authority, an independent authority within the U.S. Department of Commerce. FirstNet is continuously expanding coverage, capacity and capability of the platform while first responders currently on…

FridayMay 31, 2019 8:00 am

NetworkNewsAudio – Genprex Inc.’s (NASDAQ: GNPX) Proprietary Technology Platform Delivers Targeted Gene Therapeutics

Related Editorial Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is leveraging its patented technology platform to deliver powerful tumor-suppressing genes directly into cancer cells. Calithera Biosciences Inc. (NASDAQ: CALA) is looking for cures for cancer and other life-threatening diseases by discovering, developing and commercializing novel, small-molecule drugs that target tumor and immune cell metabolism. Adaptimmune Therapeutics plc (NASDAQ: ADAP) is developing novel cancer immunotherapy products for cancer patients by engineering T-cells to target and destroy cancer. Agenus Inc. (NASDAQ:…

WednesdayMay 29, 2019 6:00 pm

NetworkNewsAudio – Hemptown USA Interview

About Hemptown USA Hemptown USA, headquartered in Central Point, Oregon, is a proven grower of full-spectrum, feminized hemp grown using premium-seed genetics that contain less than 0.3% THC and exceptionally high cannabinoid (CBD) content of up to 20%. The company’s soil-to-oil methodology combines seasoned professionals working in handpicked agricultural microclimates located in Oregon’s famed Emerald Triangle and in Kentucky and Colorado. For more information, visit the company’s website at www.HemptownUSA.com. About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded…

ThursdayMay 09, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Developing Transformative Cancer Therapies

Related Editorial Gene therapies are gaining growing attention within the medical sector. Gene therapies help restore or replace the body’s damaged or missing genes. Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die. Gene therapies are also being developed for ailments such as migraines, skin conditions and hemophilia. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is developing gene therapies for the treatment of cancer, including its initial drug candidate, Oncoprex(TM) immunogene therapy. Spark Therapeutics Inc. (NASDAQ: ONCE) is tackling hereditary diseases through treatments that augment, suppress or replace mutated genes. Dyadic International Inc. (OTCQX: DYAI) uses…

FridayMay 03, 2019 8:00 pm

NetworkNewsAudio – Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Interview

About Wildflower Brands Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) is a Vancouver-based company developing and designing brands that focus on plant-based health and wellness products. All of the company’s brands work in synergy, toward becoming a global wellness leader. For more information, visit the company’s website at www.WildflowerBrands.co. NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://nnw.fm/WLDFF About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching.…

MondayApr 15, 2019 8:30 pm

NetworkNewsAudio – Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (Frankfurt: O3X4) Interview

About Redfund Capital Corp. Redfund intends to provide debt and equity funding in the middle to late stages of a target company’s development or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related and healthcare-related companies. For more information, visit the company’s website at www.RedfundCapital.com. NOTE TO INVESTORS: The latest news and updates relating to PNNRF are available in the company’s newsroom at http://nnw.fm/PNNRF About NetworkNewsAudio NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press…

FridayApr 12, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Raising the Bar in Cancer Therapeutics

Related Editorial Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable. Gene therapy is the next great leap forward in medicine, with several noteworthy programs underway looking to cure the incurable FDA expects 200 new gene and cell therapy INDs in next two years Genprex — and its initial product candidate Oncoprex — is pioneering a new approach to treating cancer. Built on decades of scientific research and innovation, gene therapy is the next frontier of medicine, determined to provide remedies for previously untreatable diseases and…

MondayApr 01, 2019 8:00 am

NetworkNewsAudio – SinglePoint, Inc. (SING) Establishes a Foothold within the Automotive Industry

Related Editorial Technology is transforming the automotive industry. Data is changing vehicle manufacturing and the way customers buy. Connectivity is transforming the relationships between customers and their vehicles. New technology such as blockchain provides alternative approaches to existing issues. The change affects the whole sector, from manufacturing and maintenance to sales. Some of the innovation feeds off ideas from other industries, such as the vehicle repair app created by SinglePoint Inc. (OTCQB: SING) (SING Profile). Some of it is focused on sales, as is the case for CDK Global Inc. (NASDAQ: CDK) and its dashboard to help with sales. There…

FridayMar 29, 2019 8:00 am

NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Establishing Itself as a Trailblazer in Breakthrough Cancer Treatments

Related Editorial Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer. Gene therapies are being developed to more effectively target the treatment of cancer. Non-small cell lung cancer (NCSLC) is the leading cause of cancer death. Genprex Inc. is advancing Oncoprex, shown to benefit lung cancer patients in early trials. A multiplicity of potential breakthrough treatments to fight cancer are in varying stages of clinical development, and many are focused on the promise of advanced gene therapies. Genprex Inc. (NASDAQ: GNPX) (GNPX Profile) is working to bring…

Financial news and publishing for public and private companies

Contact us: 212.418.1217

NetworkNewsAudio